Ted Turner, the media mogul and co-founder of CNN, spent his later years grappling with a progressive neurodegenerative condition that reshaped his public persona and drew global attention to a lesser-known but debilitating form of dementia. Although Alzheimer’s disease often dominates headlines, Turner’s diagnosis—Lewy body dementia (LBD)—represents a distinct and equally challenging neurological disorder. Unlike Alzheimer’s, which primarily disrupts memory, LBD is marked by a complex interplay of cognitive decline, motor symptoms and vivid hallucinations, often leaving patients and families struggling to navigate its unpredictable progression.
Lewy body dementia accounts for an estimated 10–15% of all dementia cases, making it the third most common type after Alzheimer’s and vascular dementia, according to the Alzheimer’s Association. Yet its symptoms—ranging from Parkinson-like tremors to severe visual hallucinations—frequently lead to misdiagnosis, delaying critical interventions. Turner’s public acknowledgment of his condition in 2019, when he was 89, underscored the necessitate for greater awareness, particularly among older adults and their caregivers.
The disease derives its name from abnormal deposits of a protein called alpha-synuclein, which form clumps (or “bodies”) in the brainstem, cortex, and other regions. These Lewy bodies disrupt communication between neurons, impairing movement, cognition, and autonomic functions like blood pressure regulation. While the exact cause remains unknown, researchers link LBD to a combination of genetic predisposition, environmental factors, and age-related neuronal decline. Unlike Alzheimer’s, which is characterized by amyloid plaques, LBD’s hallmark is the presence of these Lewy bodies, which can also appear in Parkinson’s disease—explaining why some patients exhibit overlapping symptoms.
What Is Lewy Body Dementia?
Lewy body dementia is an umbrella term encompassing two closely related conditions:
- Dementia with Lewy bodies (DLB): Diagnosed when cognitive symptoms (memory loss, confusion) appear first, followed by motor symptoms like rigidity or shuffling gait.
- Parkinson’s disease dementia (PDD): Diagnosed when motor symptoms (tremors, stiffness) precede cognitive decline by at least a year.
Both forms share core features, including:
- Fluctuating cognition: Patients experience periods of alertness interspersed with confusion or even temporary “freezing” of thought processes.
- Visual hallucinations: Often vivid and detailed, these can involve people, animals, or objects and may occur in up to 80% of cases, per studies published in the Journal of Alzheimer’s Disease.
- Motor symptoms: Bradykinesia (slowed movement), tremors, and postural instability mirror those seen in Parkinson’s.
- Autonomic dysfunction: Issues like low blood pressure, urinary incontinence, or constipation may arise due to disrupted nerve signaling.
- Sensitivity to antipsychotics: Medications like haloperidol can trigger severe reactions, including delirium or even death in some patients.
Unlike Alzheimer’s, which progresses steadily, LBD often follows a more variable course. Some patients experience rapid deterioration within months, while others stabilize for years. This unpredictability complicates treatment planning and caregiver support.
Ted Turner’s Diagnosis: A Public Case Study
Turner’s diagnosis was first reported in January 2019 by his family, who confirmed he had been living with Lewy body dementia for several years. In a statement, his daughter, Jane Turner, described his struggles with “hallucinations, confusion, and physical stiffness,” symptoms consistent with DLB. Turner, who had previously been active in philanthropy and media, gradually withdrew from public life, a shift attributed to his declining cognitive and physical health.
Key verified details about Turner’s condition:
- His symptoms began in his late 70s, with early signs including visual hallucinations and REM sleep behavior disorder (a condition where patients act out dreams).
- He was prescribed levodopa (a Parkinson’s medication) and cholinesterase inhibitors, though responses varied.
- His family emphasized the importance of early diagnosis, noting that many doctors initially misattributed his symptoms to Alzheimer’s or depression.
Turner’s case highlights a critical gap in dementia care: LBD is frequently underdiagnosed. A 2022 study in Neurology found that only 30% of patients with LBD received an accurate diagnosis within two years of symptom onset, often due to overlapping features with Alzheimer’s or Parkinson’s. This delay can lead to inappropriate treatments—such as antipsychotics—which worsen outcomes in LBD.
Why Misdiagnosis Is Dangerous
Lewy body dementia shares symptoms with several other conditions, creating diagnostic challenges:
- Alzheimer’s disease: Both cause memory loss, but LBD patients are more likely to experience hallucinations and motor symptoms.
- Parkinson’s disease: Up to 80% of Parkinson’s patients will develop dementia, often with Lewy bodies present. The key distinction is the timing of cognitive decline.
- Psychiatric disorders: Depression or schizophrenia can mimic LBD’s hallucinations, leading to incorrect prescriptions.
A definitive diagnosis typically requires:
- A detailed medical history and neurological exam.
- Brain imaging (MRI or PET scans) to rule out other causes like strokes or tumors.
- DAT (dopamine transporter) scans, which can detect Lewy bodies by showing reduced dopamine activity.
- In some cases, a lumbar puncture to test for biomarkers like alpha-synuclein.
Given these complexities, experts recommend consulting a neurologist or movement disorder specialist for suspected LBD. Early and accurate diagnosis is crucial, as it guides treatment and improves quality of life.
Treatment and Management
There is currently no cure for Lewy body dementia, but a combination of medications, therapies, and lifestyle adjustments can aid manage symptoms and slow progression. Key approaches include:
Medications
- Cholinesterase inhibitors (e.g., donepezil, rivastigmine): Approved for DLB, these may improve cognition and hallucinations.
- Levodopa/carbidopa: Helps with motor symptoms like rigidity and tremors.
- Avoid antipsychotics: Medications like risperidone or quetiapine can cause severe side effects, including neuroleptic malignant syndrome.
Non-Pharmacological Interventions
- Physical therapy: Maintains mobility and reduces fall risk.
- Occupational therapy: Adapts daily activities to cognitive and motor limitations.
- Speech therapy: Helps with communication challenges.
- Caregiver support: Critical for managing behavioral symptoms like agitation or hallucinations.
Research is ongoing into potential disease-modifying therapies. In 2023, a phase II trial of ganaxolone (a steroid-like drug) showed promise in reducing hallucinations and cognitive fluctuations in LBD patients, though larger studies are needed. Clinical trials like those sponsored by the Lewy Body Dementia Association remain the best hope for future breakthroughs.
Living with LBD: Challenges and Resources
Caregivers of LBD patients often face unique challenges, including:
- Unpredictable symptom fluctuations: Patients may appear lucid one moment and confused the next.
- Sundowning: Increased agitation or hallucinations in the evening.
- Sensitivity to medications: Requiring careful monitoring of prescriptions.
Organizations like the Lewy Body Dementia Association offer resources for patients and families, including:
- Caregiver training programs.
- Support groups and online forums.
- Educational materials on symptom management.
- Advocacy for improved research funding.
For individuals concerned about LBD risk, experts recommend:
- Regular neurological check-ups, especially after age 60.
- Monitoring for early signs like REM sleep behavior disorder or mild cognitive changes.
- Maintaining a healthy lifestyle, including exercise and cognitive stimulation.
What’s Next for Research and Awareness?
The global dementia research community is prioritizing LBD, with key developments in 2025–2026 including:
- A multi-center trial testing alpha-synuclein immunotherapy to halt Lewy body formation (results expected in 2027).
- Expanded use of AI-driven diagnostic tools to improve early detection.
- Increased funding from organizations like the National Institute on Aging for LBD-specific research.
Public figures like Ted Turner play a vital role in raising awareness. His openness about LBD has helped destigmatize the condition and encouraged others to seek accurate diagnoses. As research advances, the hope is that LBD will join Alzheimer’s and Parkinson’s as a condition with clearer treatment pathways and better support for patients and families.
Key Takeaways
- Lewy body dementia (LBD) is a progressive neurodegenerative disorder marked by cognitive decline, hallucinations, and motor symptoms.
- It is often misdiagnosed as Alzheimer’s or Parkinson’s, delaying critical interventions.
- Symptoms include fluctuating cognition, visual hallucinations, and sensitivity to antipsychotic medications.
- While there is no cure, medications like cholinesterase inhibitors and levodopa can manage symptoms.
- Caregiver support and early diagnosis are key to improving quality of life.
- Research is advancing, with trials targeting alpha-synuclein and new diagnostic tools.
If you or a loved one are experiencing symptoms of LBD, consult a neurologist for evaluation. For resources and support, visit the Lewy Body Dementia Association or contact local dementia care organizations.
Next checkpoint: The National Institute on Aging’s 2026 funding announcements, expected in late June, may include grants for LBD research. Stay informed by following updates from the Lewy Body Dementia Association.
Share your experiences or questions in the comments below. Have you or a loved one been affected by LBD? Your stories can help others navigate this challenging condition.